Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

Lexeo Therapeutics (NASDAQ:LXEO) had its price target cut by Chardan Capital from $22.00 to $20.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, April 8th. Royal Bank of Canada dropped their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 25th. Finally, Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $21.80.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $2.70 on Tuesday. Lexeo Therapeutics has a 52-week low of $1.45 and a 52-week high of $19.50. The stock has a 50 day simple moving average of $3.06 and a 200 day simple moving average of $5.01. The firm has a market capitalization of $89.63 million, a PE ratio of -0.85 and a beta of 1.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.19). Sell-side analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Institutional investors have recently made changes to their positions in the company. Allostery Investments LP purchased a new stake in Lexeo Therapeutics during the fourth quarter valued at about $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics during the fourth quarter worth approximately $46,000. Price T Rowe Associates Inc. MD bought a new position in shares of Lexeo Therapeutics in the fourth quarter worth approximately $69,000. SG Americas Securities LLC bought a new stake in Lexeo Therapeutics in the fourth quarter valued at $72,000. Finally, Wells Fargo & Company MN boosted its holdings in Lexeo Therapeutics by 49.9% in the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company’s stock valued at $73,000 after acquiring an additional 3,714 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.